Pharvaris N.V. (PHVS) is in Healthcare, Biotechnology, based in Switzerland, listed on NasdaqGS. Market cap 2.18B USD. 52-week range 20.65 to 43.25 USD. Data as of 2026-10-09.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in ...